September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Growing Role of Immunotherapy as Treatment for Lung Cancer
March 3rd 2018Marina C. Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses current advancements with immunotherapy as first- and second-line treatments for patients with lung cancer.
Watch
Levy Highlights Novel Combinations in NSCLC
March 2nd 2018A novel regimen of immunotherapy, angiogenesis inhibition, and chemotherapy brings promising outcomes for patients with non-small cell lung cancer (NSCLC). The synergic combination, notes Benjamin P. Levy, MD, would be exciting to have in the landscape.
Read More
Identifying Patients With Lung Cancer Who Benefit From Immunotherapy
February 24th 2018Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology at Fox Chase Cancer Center, discusses biomarkers that may help identify patients with lung cancer who can benefit from immunotherapy agents. Since the introduction of these agents, PD-L1 has been used as a potential biomarker for selecting patients that may benefit from treatment. As PD-L1 is not completely reliable, there is interest in developing additional biomarkers.
Watch
Avelumab Does Not Improve OS Over Docetaxel in NSCLC, Phase III Trial Shows
February 23rd 2018The primary endpoint of improving overall survival was not met in the phase III JAVELIN Lung 200 Trial of avelumab in patients with non–small cell lung cancer, according to Merck KGaA and Pfizer, the co-developers of avelumab.
Read More
Jean-Charles Soria to Receive TAT 2018 Honorary Award for Cancer Drug Development
February 20th 2018Jean-Charles Soria, MD, PhD, will be honored with the Targeted Anticancer Therapies 2018 Honorary Award for cancer drug development. Soria has played a large part in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy for the last 15 years.
Read More
Durvalumab Granted FDA Approval for Locally Advanced NSCLC
February 17th 2018Based on results from the phase III PACIFIC trial, durvalumab has been granted approval by the FDA for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.
Read More
Promising Activity Seen from ERK1/2 Inhibitor in MAPK/ERK Mutations and BRAF/MEK Resistance
February 17th 2018Ulixertinib, a novel ERK1/2 inhibitor, demonstrated encouraging antitumor activity in patients with solid tumors harboring mutations in the MAPK/ERK pathway, according to the results of a phase I study published in <em>Cancer Discovery</em>.
Read More
What Would CMS Proposed Coverage Decision for Next-Generation Sequencing Mean for Oncologists?
February 16th 2018The day when oncologists can order a Medicare-covered next-generation sequencing diagnostic test may be near at hand, but once this change goes into effect, will oncologists be limited to certain tests, labs, and cancer settings? The answer is unclear.
Read More
Abscopal Effect Induction Among Patients With Metastatic Non-Small Cell Lung Cancer
February 14th 2018The prognosis for patients with metastatic non–small cell lung cancer (NSCLC) is poor. However, with recent trials showing improved overall survival with checkpoint inhibitors compared with standard chemotherapy, disease management is changing.
Read More
Lorlatinib Granted Priority Review by FDA for ALK+ NSCLC
February 13th 2018A new drug application for lorlatinib for use in patients with <em>ALK</em>-positive metastatic non–small cell lung cancer who have progressed on 1 or more ALK tyrosine kinases inhibitors has been granted a priority review by the FDA.
Read More
Immunotherapy Combination Boosts PFS for Treatment of High TMB NSCLC
February 9th 2018Based on data from part 1a of the phase III CheckMate-227 trial, nivolumab (Opdivo) and ipilimumab (Yervoy) in combination show improved progression-free survival (PFS) versus with chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB) non–small cell lung cancer (NSCLC).
Read More
Gray Sheds Light on Considerations When Treating NSCLC With Immunotherapy
February 5th 2018Jhanelle E. Gray, MD, recently shared the treatment considerations and decisions she makes when treating patients with non–small cell lung cancer, with a special focus on immunotherapy. Gray, associate member, Director of Thoracic Clinical Research, Moffitt Cancer Center, Tampa, Florida, explained her treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Kathy Albain Named First Huizenga Family Endowed Chair at Loyola University Chicago
January 24th 2018Kathy S. Albain, MD, has been named the inaugural Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine. Funded by Heidi Huizenga, one of Albain’s beholden patients, her husband, and her family, the endowed chair recognizes Albain’s notable contributions as a physician, research, teacher and mentor.
Read More
Afatinib Approval for Lung Cancer Expanded by FDA
January 15th 2018The frontline indication for afatinib (Gilotrif) has been expanded by the FDA to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon <em>EGFR</em> alterations in L861Q, G719X, and/or S768I.
Read More